SEC Tracker
Get the app

Orchestra BioMed Holdings OBIO

Orchestra BioMed Holdings Q1 FY24: revenue $620K; diluted EPS −$0.38

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Orchestra BioMed Holdings reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$620KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$13.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.38No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$23.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$13.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Orchestra BioMed Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Myomo MYO public float $62M, Jun 30, 2025
  2. Edap TMS EDAP public float $62M, Jun 30, 2025
  3. InspireMD NSPR public float $61M, Jun 30, 2025
  4. Cytosorbents CTSO public float $61M, Jun 30, 2025
  5. Pro Dex PDEX public float $68M, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.